Cryorecovery/Cell Product Collection, Handling and Installation

How AAGP® could promote cell survival in cryopreserved products

The technique of cryopreservation dramatically furthered scientific research by allowing for the preservation, storage, and retrieval of studied cells. But the products preserved via cryopreservation are still found to be susceptible to cell death due to metabolic impairment during the recovery process.

At ProtoKinetix, we’re in the beginning stages of exploring how the protective qualities of AAGP® can help promote cell survival of organoids, stem cells for therapies, and CAR-T’s cells for oncology and cancer therapy during cryorecovery.


The causes of decreased cell viability

When performed correctly, cryopreservation can effectively store a variety of cell products almost indefinitely. The true challenge lies in resuscitating the line — bringing the product out of cold storage for revival and further study. While some attrition is to be expected regardless of the details of the cryorecovery, various factors will influence the overall success of the operation.

Factors affecting cell viability in cryopreservation

  • Genetic background or strain
  • Recovery protocol
  • Media Cryo media components
  • Type and duration of cold storage
Microscope image

Control and risk management for cryorecovery

Clearly, optimizing the recovery of the maximum amount of human tissue, cells, or other cryopreserved products is a critical goal. Effective biopreservation of embryonic or stem cells, particularly induced pluripotent stem (iPS) cells, is especially important for research, drug discovery, and other purposes.

Good manufacturing practices are a vital component in ensuring the longevity of these cell lines. Best practices include adherence to established protocols and guarding against contamination, among others. However, there may be a way to take these safeguards a step further.

AAGP® as a potential solution

The protective properties of AAGP® could potentially support the increased viability of cryopreserved cells and cell products when added to the cryopreservation process. By exposing preserved stem cells to AAGP®, we have found a measurable improvement in maintaining stem cell numbers after recovery. Stem cell viability increased 36-38% in our preliminary testing — an encouraging advantage.

ProtoKinetix research and studies

Read more about the results of our exploration into cryorecovery and cell viability using AAGP®.

Effect of AAGP® on preserving cell survival number in human and mouse neural stem cells during cryopreservation. 

View the research

Market potential for cryopreservation

The market for cryopreservation is predicted to expand rapidly, with a compound annual growth rate of more than 22% over the next 5 years. Already a $3.4 billion market from 2017, the United States in particular is expected to see over $1 billion in growth, with Asia (Pacific) catching up fast thanks to R&D efforts overseas.

Major market drivers for this industry include an increasing hunt for drug development and pharmaceutical research, declining fertility, and a rising number of novel freezing techniques, mediums, and systems.

We’re striving to introduce AAGP® and its powerful potential amid this competition.


Support our research into extending and improving the viability of stem cells, mouse embryos and other cryopreserved products, while also supporting your financial future. Contact your broker or reach out to our team at ProtoKinetix to learn about potential investment options.

  • This field is for validation purposes and should be left unchanged.